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Sarah Salinas (IMG-Montpellier) discussed the utility of 
 adenovirus-derived canine serotype 2 (CAV-2) vectors. Development 
of CAV-2 vectors has overcome the potential toxicity associated with 
earlier adenovirus vectors, providing an effi cacious vector that can 
carry larger payloads than lentivirus or AAV. As well as reviewing 
the biology of CAV-2 and its modifi cations for use in research, this 
talk highlighted several neurobiological studies that successfully 
used CAV-2 for gene transfer. Another exciting use of adenoviral 
systems was introduced by Anthony Pickering (Bristol University), 
who described the manipulation of the function of noradrenergic 
neurons involved in pain control. By transducing noradrenergic 
neurons in the pons with a virus expressing a potassium channel, 
he was able to produce modality specifi c hyperalgesia. He went on 
to suggest how these results will form a basis for future approaches 
to induce analgesia by activating pontine neurons.
While AAV, adenovirus and lentivirus are perhaps the most fre-
quently used vectors for neuroscience applications, other viruses 
with different biological properties have proven useful. Nigel Fraser 
(University of Pennsylvania) provided an excellent overview of the 
development of the herpes simplex virus (HSV) as a powerful tool 
for research. While development of this virus as an experimental 
tool is at an early stage, its relatively large genome (152 kb) gives 
the potential to carry large payloads and Dr. Fraser provided good 
examples for its potential use to treat mucopolysaccharide disease 
and cancer, as well as for the tracing of neural connectivity. Different 
advantages can be obtained from use of alphaviral vectors, such as 
Semliki Forest and Sindbis viruses. These were highlighted by Markus 
Ehrengruber (KSHP), who provided a comprehensive overview of 
the use of alphaviral vectors, as well as the measles virus, in neurobi-
ology. He illustrated a good example of the use of the Semliki Forest 
virus expression vector to study the function of the synaptic protein 
Homer. Particular strengths of the alphaviral vectors are the rapid 
and high level of transgene expression that can be obtained, although 
potential toxicity is a drawback for long-term expression studies.
The fi nal session of the meeting showcased examples of viruses 
used in vivo to address basic neurobiological questions. Peer Wulff 
(ENI-Aberdeen) described a powerful approach to specifi cally tar-
get expression of a toxin in interneurons in the brain by combined 
use of a mouse line that expresses Cre recombinase specifi cally in 
interneurons, with an AAV-loxP-toxin recombinant virus. Using 
this system, he specifi cally blocked release of neurotransmitters 
from interneurons in the hippocampus. Hélène Marie (ENI-Rome) 
then illustrated the successful use of the recombinant Sindbis virus 
system in identifying the effects of a constitutive mutant form 
of the transcription factor CREB on synaptic transmission and 
memory formation by combining its use for in vivo expression 
with electrophysiological and behavioral analyses. Next, Andreas 
Tools to manipulate gene expression in defi ned populations of neu-
rons are crucial for progress in understanding the brain and for treat-
ment of nervous system disorders. An increasingly popular approach 
for experimental and therapeutic manipulation of neuronal gene 
expression is to transduce neurons using viral vectors. The ENINET 
(www.eni-net.org) sponsored workshop “Virus-based technologies 
for investigating function and  pathology of the nervous system” took 
place on October 1st–2nd, 2009, at the European Brain Research 
Institute (ENI-Rome institution) in Rome, Italy. This workshop 
addressed the basic biology of viruses, the strengths and weaknesses 
of different viral systems for experimental and therapeutic appli-
cations, new developments in virus-based technologies and their 
application in investigating nervous system function.
The workshop began with an in depth introduction to two of the 
most frequently used viral vectors. Isabelle Barde (EPFL) provided 
a comprehensive overview of the development of lentiviruses as 
research tools. Lentiviruses, such as human and feline immunodefi -
ciency viruses, have been turned into fl exible and safe tools for intro-
ducing genetic manipulations into various types of cells including 
neurons. Applications now extend from routine use of lentivirus vec-
tors to transduce cultured neurons, to in vivo expression of transgenes 
and development of transgenic animals. The next speaker, Nicholas 
Mazarakis (Imperial College), reviewed the use of both lentivirus 
and adeno- associated virus (AAV) vectors for gene therapy. After an 
interesting introduction to the engineering of these viruses for gene 
transfer in humans, he demonstrated their potential use for several 
neurological disorders including Parkinson’s disease, for which he pro-
vided very exciting proof of principle data for reversal of Parkinsonian 
symptoms. Further examples of the potential clinical importance 
of AAV vectors were provided in a later talk by Jean-Michel Heard 
(Institut Pasteur), who gave a detailed account of the development 
of AAV vectors for human gene therapy to treat lysosomal storage 
disease. This important example illustrates the progression from 
recombinant vector conception to ongoing human clinical trials.
Several speakers highlighted the diverse applications of lentivi-
rus vectors. Melanie White (Edinburgh University) described an 
example of the use of a lentiviral vector-encoded silencing RNA as 
a potential therapeutic tool to treat prion diseases. Oliver Schlüter 
(ENI-Göttingen) described the use of a lentivirus vector system to 
examine the role of the post-synaptic protein PSD95 in synaptic 
transmission. He explained how he developed a powerful molecular 
replacement strategy using a combination of lentivirus-encoded 
silencing RNAs to knockdown native PSD95 and mutant PSD95 
transgene constructs to rescue function. Angel Barco (ENI-Alicante) 
described the development of an exciting novel gain-of-function 
approach using lentiviruses to unveil the transcriptional programs 
of specifi c transcription factors.
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Frick (ENI-Bordeaux) provided an introduction to the use of rabies 
viruses in neuroscience, focusing on its well-known characteristic 
of retrograde transport. He summarized his work using this virus 
to label the mono-synaptic input map of neurons in the cortex 
and retina. Michael Häusser (ENI-London) nicely concluded 
this fi nal session by showing us how his group combines in vivo 
shadow patching, in vivo single cell electroporation and in vivo 
rabies infection of cortical neurons to elucidate the wiring maps 
of individual neurons.
In conclusion, the workshop demonstrated versatile applications 
of various viral vectors for basic neuroscience research and for 
human gene therapy. Some of these vectors have been the focus of 
considerable recent developments to make them invaluable research 
tools. However, a recurring theme was that work remains to be done 
to optimize even the most advanced vectors for in vivo delivery and 
target specifi city; while other relatively uncharacterized viruses may 
provide novel and potentially useful properties that would make 
them attractive as alternative experimental and therapeutic tools.
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